These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35909902)

  • 1. A Systematic Review and Meta-Analysis on the Prognostic Value of BRCA Mutations, Homologous Recombination Gene Mutations, and Homologous Recombination Deficiencies in Cancer.
    Shao C; Chang MS; Lam FC; Marley AR; Tang H; Song Y; Miller C; Brown M; Wan I; Han J; Adeboyeje G
    J Oncol; 2022; 2022():5830475. PubMed ID: 35909902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies.
    Shao C; Wan J; Lam FC; Tang H; Marley AR; Song Y; Miller C; Brown M; Han J; Adeboyeje G
    Environ Mol Mutagen; 2022 Jul; 63(6):308-316. PubMed ID: 36054589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.
    Pujade-Lauraine E; Brown J; Barnicle A; Wessen J; Lao-Sirieix P; Criscione SW; du Bois A; Lorusso D; Romero I; Petru E; Yoshida H; Vergote I; Colombo N; Hietanen S; Provansal M; Schmalfeldt B; Pignata S; Martín Lorente C; Berton D; Runnebaum IB; Ray-Coquard I
    JCO Precis Oncol; 2023 Jan; 7():e2200258. PubMed ID: 36716415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis.
    Batalini F; DaSilva LL; Campoverde L; Comini ACM; Carvalho BM; Nogueira W; Silveira H; Ernst BJ; Mina LA
    Chin Clin Oncol; 2023 Jun; 12(3):21. PubMed ID: 37211773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishing the homologous recombination score threshold in metastatic prostate cancer patients to predict the efficacy of PARP inhibitors.
    Zhao D; Wang A; Li Y; Cai X; Zhao J; Zhang T; Zhao Y; Dong Y; Zhou F; Li Y; Wang J
    J Natl Cancer Cent; 2024 Sep; 4(3):280-287. PubMed ID: 39281716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker Testing Journey Among Patients with Advanced Solid Tumors and Treatment Patterns by Homologous Recombination Repair Status: A Clinico-Genomic Database Study.
    Shao C; Ren Y; Zhou H; Lee LC; Chen C; Dettman EJ; Cristescu R; Gozman A; Jin F; Zhou W
    Adv Ther; 2024 Feb; 41(2):759-776. PubMed ID: 38169059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Homologous Recombination Repair Biomarkers and Survival in Patients With Solid Tumors.
    Shao C; Ren Y; Zhou H; Chen C; Dettman EJ; Lee LC; Cristescu R; Gozman A; Jin F; Zhou W
    JCO Precis Oncol; 2023 Sep; 7():e2300195. PubMed ID: 37972338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homologous Recombination Abnormalities Associated With
    Albitar M; Zhang H; Pecora A; Waintraub S; Graham D; Hellmann M; McNamara D; Charifa A; De Dios I; Ma W; Goy A
    Breast Cancer (Auckl); 2023; 17():11782234231198979. PubMed ID: 37789896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
    Lee CK; Friedlander ML; Tjokrowidjaja A; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Bloomfield R; Goble S; Wang P; Glasspool RM; Scott CL;
    Cancer; 2021 Jul; 127(14):2432-2441. PubMed ID: 33740262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial.
    Koole SN; Schouten PC; Hauke J; Kluin RJC; Nederlof P; Richters LK; Krebsbach G; Sikorska K; Alkemade M; Opdam M; Schagen van Leeuwen JH; Schreuder HWR; Hermans RHM; de Hingh IHJT; Mom CH; Arts HJG; van Ham M; van Dam P; Vuylsteke P; Sanders J; Horlings HM; van de Vijver KK; Hahnen E; van Driel WJ; Schmutzler R; Sonke GS; Linn SC
    Int J Cancer; 2022 Oct; 151(8):1394-1404. PubMed ID: 35583992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
    Hodgson D; Lai Z; Dearden S; Barrett JC; Harrington EA; Timms K; Lanchbury J; Wu W; Allen A; Senkus E; Domchek SM; Robson M
    Ann Oncol; 2021 Dec; 32(12):1582-1589. PubMed ID: 34500047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly(adenosine diphosphate-ribose) polymerase inhibitor combinations in first-line metastatic castrate-resistant prostate cancer setting: a systematic review and meta-analysis.
    Sayyid RK; Klaassen Z; Berlin A; Roy S; Brandão LR; Bernardino R; Chavarriaga J; Jiang DM; Spratt DE; Fleshner NE; Wallis CJD
    BJU Int; 2023 Dec; 132(6):619-630. PubMed ID: 37461140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer.
    Wen H; Feng Z; Ma Y; Liu R; Ou Q; Guo Q; Shen Y; Wu X; Shao Y; Bao H; Wu X
    BMC Cancer; 2022 May; 22(1):550. PubMed ID: 35578198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
    Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
    Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma.
    Feng Z; Shao D; Cai Y; Bi R; Ju X; Chen D; Song C; Chen X; Li J; An N; Li Y; Zhou Q; Xiu Z; Zhu S; Wu X; Wen H
    J Ovarian Res; 2023 Mar; 16(1):53. PubMed ID: 36922847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis.
    Chai Y; Chen Y; Zhang D; Wei Y; Li Z; Li Q; Xu B
    J Pers Med; 2022 Feb; 12(2):. PubMed ID: 35207810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of homologous recombination repair/BReast CAncer (BRCA) gene alterations on survival in a real-world setting of metastatic prostate cancer.
    Wenzel M; Hoeh B; Koll F; Humke C; Fassl A; Reis H; Wild P; Steuber T; Graefen M; Tilki D; Traumann M; Banek S; Chun FKH; Mandel P
    BJU Int; 2025 Jan; 135(1):117-124. PubMed ID: 38982928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of PARP inhibitors in homologous recombination proficient ovarian cancer: meta-analysis.
    Skelin M; Šarčević D; Lešin Gaćina D; Mucalo I; Dilber I; Javor E
    J Chemother; 2023 Apr; 35(2):150-157. PubMed ID: 35550005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).
    Sharma P; Barlow WE; Godwin AK; Pathak H; Isakova K; Williams D; Timms KM; Hartman AR; Wenstrup RJ; Linden HM; Tripathy D; Hortobagyi GN; Hayes DF
    Ann Oncol; 2018 Mar; 29(3):654-660. PubMed ID: 29293876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
    Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
    Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.